<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35137155</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1945-7197</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical endocrinology and metabolism</Title>
          <ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Outcomes of Initial Management Strategies in Patients With Autoimmune Lymphocytic Hypophysitis: A Systematic Review and Meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>1170</StartPage>
          <EndPage>1190</EndPage>
          <MedlinePgn>1170-1190</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1210/clinem/dgab839</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT">Lymphocytic hypophysitis (LyHy) is characterized by inflammation of the pituitary and or neuroinfundibulum and is uncommon. Treatment options include observation, high-dose glucocorticoids (HD-GCs) or surgery. Optimal first-line management strategy, however, remains unknown.</AbstractText>
          <AbstractText Label="OBJECTIVE">This work aimed to assess response to first-line treatment options (observation, HD-GCs, or surgery) of clinically relevant outcomes (symptomatic, hormonal, and radiographic improvement) among patients with LyHy.</AbstractText>
          <AbstractText Label="METHODS">A systematic review was conducted in 6 databases through 2020. Meta-analysis was conducted when feasible using a random-effects model.</AbstractText>
          <AbstractText Label="RESULTS">We included 33 studies reporting on 591 patients (423 women, 72%) with LyHy. Improvement/resolution of anterior pituitary dysfunction was highest when HD-GCs was first-line treatment. Surgery was associated with the greatest proportion of patients who had regression on imaging. Subgroup analysis comparing HD-GCs to observation showed the odds of anterior pituitary hormone recovery (OR 3.41; 95% CI, 1.68-6.94) or radiographic regression (OR 3.13; 95% CI, 1.54-6.36) were higher with HD-GCs, but so was the need for additional forms of treatment (OR 4.37; 95% CI, 1.70-11.22). No statistically significant difference was seen in recovery of diabetes insipidus (OR 0.9; 95% CI, 0.26-3.10). Certainty in these estimates was very low.</AbstractText>
          <AbstractText Label="CONCLUSION">Observation and use of HD-GCs both are successful first-line management strategies in LyHy. Although use of HD-GCs was associated with increased recovery of anterior pituitary hormone deficit, it also was associated with greater likelihood of additional treatment after withdrawal. Optimal dosing and duration of HD-GCs remains unknown.</AbstractText>
          <CopyrightInformation>© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Donegan</LastName>
            <ForeName>Diane</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-5091-9582</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana 46206, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saeed</LastName>
            <ForeName>Zeb</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana 46206, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delivanis</LastName>
            <ForeName>Danae A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murad</LastName>
            <ForeName>Mohammad Hassan</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota 55905, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Honegger</LastName>
            <ForeName>Juergen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, University of Tübingen, 72076 Tübingen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amereller</LastName>
            <ForeName>Felix</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Medizinische Klinik und Poliklinik IV, LMU Klinikum, 80336 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oguz</LastName>
            <ForeName>Seda Hanife</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Hacettepe University Medical School, 06230 Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erickson</LastName>
            <ForeName>Dana</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bancos</LastName>
            <ForeName>Irina</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0001-9332-2524</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K23 DK121888</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K23DK121888</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>0375362</NlmUniqueID>
        <ISSNLinking>0021-972X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010908">Pituitary Hormones, Anterior</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C580003">Combined Pituitary Hormone Deficiency</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000069281" MajorTopicYN="Y">Autoimmune Hypophysitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007018" MajorTopicYN="Y">Hypopituitarism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010900" MajorTopicYN="Y">Pituitary Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010908" MajorTopicYN="Y">Pituitary Hormones, Anterior</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">adenohypophysitis</Keyword>
        <Keyword MajorTopicYN="Y">autoimmunity</Keyword>
        <Keyword MajorTopicYN="Y">infundibuloneurohypophysitis</Keyword>
        <Keyword MajorTopicYN="Y">panhypophysitis</Keyword>
        <Keyword MajorTopicYN="Y">pituitary</Keyword>
        <Keyword MajorTopicYN="Y">treatment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35137155</ArticleId>
        <ArticleId IdType="pmc">PMC8947799</ArticleId>
        <ArticleId IdType="doi">10.1210/clinem/dgab839</ArticleId>
        <ArticleId IdType="pii">6432236</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Duan K, Asa SL, Winer D, Gelareh Z, Gentili F, Mete O. Xanthomatous hypophysitis is associated with ruptured Rathke’s cleft cyst. Endocr Pathol. 2017;28(1):83-90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28120170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in endocrinology: hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018;179(3):R151-R163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29880706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chiloiro S, Tartaglione T, Angelini F, et al. . 
An overview of diagnosis of primary autoimmune hypophysitis in a prospective single-center experience. Neuroendocrinology. 2017;104(3):280-290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27165294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sautner D, Saeger W, Lüdecke DK, Jansen V, Puchner MJ. Hypophysitis in surgical and autoptical specimens. Acta Neuropathol. 1995;90(6):637-644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8615086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fehn M, Sommer C, Ludecke DK, Plockinger U, Saeger W. Lymphocytic hypophysitis: light and electron microscopic findings and correlation to clinical appearance. Endocr Pathol. 1998;9(1):71-78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12114664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Honegger J, Fahlbusch R, Bornemann A, et al. . 
Lymphocytic and granulomatous hypophysitis: experience with nine cases. Neurosurgery. 1997;40(4):713-722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9092844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leung GK, Lopes MB, Thorner MO, Vance ML, Laws ER Jr. Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg. 2004;101(2):262-271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15309917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26(5):599-614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15634713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Bellis A, Bizzarro A, Bellastella A. Pituitary antibodies and lymphocytic hypophysitis. Best Pract Res Clin Endocrinol Metab. 2005;19(1):67-84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15826923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Beressi N, Beressi JP, Cohen R, Modigliani E. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris). 1999;150(4):327-341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10519020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab. 1995;80(8):2302-2311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7629223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy. Clin Endocrinol (Oxf). 2010;73(1):18-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Menon SK, Sarathi V, Bandgar TR, Menon PS, Goel N, Shah NS. Autoimmune hypophysitis: a single centre experience. Singapore Med J. 2009;50(11):1080-1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19960164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khare S, Jagtap VS, Budyal SR, et al. . 
Primary (autoimmune) hypophysitis: a single centre experience. Pituitary. 2015;18(1):16-22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24375060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kyriacou A, Gnanalingham K, Kearney T. Lymphocytic hypophysitis: modern day management with limited role for surgery. Pituitary. 2017;20(2):241-250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27778295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gutenberg A, Hans V, Puchner MJ, et al. . 
Primary hypophysitis: clinical-pathological correlations. Eur J Endocrinol. 2006;155(1):101-107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16793955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oguz SH, Soylemezoglu F, Sendur SN, et al. . 
Clinical characteristics, management, and treatment outcomes of primary hypophysitis: a monocentric cohort. Horm Metab Res. 2020;52(4):220-227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32268423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang S, Wang L, Yao Y, et al. . 
Primary lymphocytic hypophysitis: clinical characteristics and treatment of 50 cases in a single centre in China over 18 years. Clin Endocrinol (Oxf). 2017;87(2):177-184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28423475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Selch MT, DeSalles AA, Kelly DF, et al. . 
Stereotactic radiotherapy for the treatment of lymphocytic hypophysitis. Report of two cases. J Neurosurg. 2003;99(3):591-596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12959451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ray DK, Yen CP, Vance ML, Laws ER, Lopes B, Sheehan JP. Gamma Knife surgery for lymphocytic hypophysitis. J Neurosurg. 2010;112(1):118-121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19558303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lupi I, Manetti L, Raffaelli V, et al. . 
Diagnosis and treatment of autoimmune hypophysitis: a short review. J Endocrinol Invest. 2011;34(8):e245-e252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21750396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Honegger J, Buchfelder M, Schlaffer S, et al. ; Pituitary Working Group of the German Society of Endocrinology . Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100(9):3460-3469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26091204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lupi I, Cosottini M, Caturegli P, et al. . 
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. Eur J Endocrinol. 2017;177(2):127-135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28626085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chiloiro S, Tartaglione T, Capoluongo ED, et al. . 
Hypophysitis outcome and factors predicting responsiveness to glucocorticoid therapy: a prospective and double-arm study. J Clin Endocrinol Metab. 2018;103(10):3877-3889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30085134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Amereller F, Küppers AM, Schilbach K, Schopohl J, Störmann S. Clinical characteristics of primary hypophysitis—a single-centre series of 60 cases. Exp Clin Endocrinol Diabetes. 2021;129(3):234-240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32770534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Angelousi A, Cohen C, Sosa S, et al. . 
Clinical, endocrine and imaging characteristics of patients with primary hypophysitis. Horm Metab Res. 2018;50(4):296-302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29458219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Donegan D, Saeed Z, Delivanis D, et al. . 
Supplementary data for “Outcomes of management strategies in patients with autoimmune lymphocytic hypophysitis: a systematic review and meta-analysis.” Quality assessment appendix 1 and 2. Uploaded July 7, 2021. 10.6084/m9.figshare.14924289.v1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6084/m9.figshare.14924289.v1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60-63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6234235</ArticleId>
            <ArticleId IdType="pubmed">29420178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wells GA, Shea B, O’Connell D, et al. . 
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed November 28, 2021. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation>
        </Reference>
        <Reference>
          <Citation>
Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974-978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23963506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc. 2017;92(3):423-433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28259229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahmadi J, Meyers GS, Segall HD, Sharma OP, Hinton DR. Lymphocytic adenohypophysitis: contrast-enhanced MR imaging in five cases. Radiology. 1995;195(1):30-34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7892490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crock PA. Cytosolic autoantigens in lymphocytic hypophysitis. J Clin Endocrinol Metab. 1998;83(2):609-618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9467582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Flanagan DE, Ibrahim AE, Ellison DW, Armitage M, Gawne-Cain M, Lees PD. Inflammatory hypophysitis—the spectrum of disease. Acta Neurochir (Wien). 2002;144(1):47-56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11807646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guo S, Wang C, Zhang J, Tian Y, Wu Q. Diagnosis and management of tumor-like hypophysitis: a retrospective case series. Oncol Lett. 2016;11(2):1315-1320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4734295</ArticleId>
            <ArticleId IdType="pubmed">26893737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Imber BS, Lee HS, Kunwar S, Blevins LS, Aghi MK. Hypophysitis: a single-center case series. Pituitary. 2015;18(5):630-641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25534888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Imura H, Nakao K, Shimatsu A, et al. . 
Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med. 1993;329(10):683-689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8345854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Korkmaz OP, Sahin S, Ozkaya HM, et al. . 
Primary hypophysitis: experience of a single tertiary center. Exp Clin Endocrinol Diabetes. 2021;129(1):14-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31234218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Panigrahi M, Kumari M, Vooturi S. Corticosteroids in the management of lymphocytic hypophysitis: case series. Neurol India. 2018;66(2):400-404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29547161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Park SM, Bae JC, Joung JY, et al. . 
Clinical characteristics, management, and outcome of 22 cases of primary hypophysitis. Endocrinol Metab (Seoul). 2014;29(4):470-478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4285029</ArticleId>
            <ArticleId IdType="pubmed">25325267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pérez G, Almeda-Valdés P, Cuevas-Ramos D, Juárez-Comboni SC, Higuera-Calleja J, Gómez-Pérez FJ. Hypophysitis autoimmune. Case series and literature review [article in Spanish]. Gac Med Mex. 2013;149(2):229-236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23652190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schaefers J, Cools M, De Waele K, et al. . 
Clinical presentation and outcome of children with central diabetes insipidus associated with a self-limited or transient pituitary stalk thickening, diagnosed as infundibuloneurohypophysitis. Clin Endocrinol (Oxf). 2017;87(2):171-176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28444954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tauziede-Espariat A, Polivka M, Bouazza S, et al. . 
The prevalence of IgG4-positive plasma cells in hypophysitis: a possible relationship to IgG4-related disease. Clin Neuropathol. 2015;34(4):181-192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25828777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tirosh A, Hirsch D, Robenshtok E, et al. . 
Variations in clinical and imaging findings by time of diagnosis in females with hypopituitarism attributed to lymphocytic hypophysitis. Endocr Pract. 2016;22(4):447-453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26595515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu Q, Qian K, Jia G, et al. . 
Clinical features, magnetic resonance imaging, and treatment experience of 20 patients with lymphocytic hypophysitis in a single center. World Neurosurg. 2019;127:e22-e29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30790734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heaney AP, Sumerel B, Rajalingam R, Bergsneider M, Yong WH, Liau LM. HLA markers DQ8 and DR53 are associated with lymphocytic hypophysitis and may aid in differential diagnosis. J Clin Endocrinol Metab. 2015;100(11):4092-4097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26317559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iuliano SL, Laws ER. The diagnosis and management of lymphocytic hypophysitis. Expert Rev Endocrinol Metab. 2011;6(6):777-783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30780867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kristof RA, Van Roost D, Klingmüller D, Springer W, Schramm J. Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? J Neurol Neurosurg Psychiatry. 1999;67(3):398-402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736542</ArticleId>
            <ArticleId IdType="pubmed">10449568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakata Y, Sato N, Masumoto T, et al. . 
Parasellar T2 dark sign on MR imaging in patients with lymphocytic hypophysitis. AJNR Am J Neuroradiol. 2010;31(10):1944-1950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7964016</ArticleId>
            <ArticleId IdType="pubmed">20651017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Honegger J, Schlaffer S, Menzel C, et al. ; Pituitary Working Group of the German Society of Endocrinology . Diagnosis of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100(10):3841-3849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26262437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caturegli P, Di Dalmazi G, Lombardi M, et al. . 
Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225-3235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5225294</ArticleId>
            <ArticleId IdType="pubmed">27750046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cosman F, Post KD, Holub DA, Wardlaw SL. Lymphocytic hypophysitis. Report of 3 new cases and review of the literature. Medicine (Baltimore). 1989;68(4):240-256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2661963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Honegger J, Giese S. Acute pituitary disease in pregnancy: how to handle hypophysitis and Sheehan’s syndrome. Minerva Endocrinol. 2018;43(4):465-475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29463076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Buxton N, Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. Br J Neurosurg. 2001;15(3):242-245; discussion 245-246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11478060</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
